NASDAQ · PRQR
Healthcare · Biotechnology
$1.29
Down-$0.05 (-3.88%)
Updated Oct 26, 2026, 11:57 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRQR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
PRQR closed at $1.24 after 21 trading sessions, down 24.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.28 | $1.32 | $1.22 | $1.24 | 939.06K |
| Oct 23, 2026 | $1.33 | $1.36 | $1.24 | $1.29 | 1.79M |
| Oct 22, 2026 | $1.36 | $1.39 | $1.32 | $1.33 | 569.78K |
| Oct 21, 2026 | $1.38 | $1.42 | $1.36 | $1.37 | 649.19K |
| Oct 20, 2026 | $1.31 | $1.38 | $1.31 | $1.38 | 938.62K |
| Oct 19, 2026 | $1.35 | $1.37 | $1.31 | $1.31 | 752.87K |
| Oct 16, 2026 | $1.45 | $1.49 | $1.30 | $1.31 | 1.06M |
| Oct 15, 2026 | $1.48 | $1.485 | $1.44 | $1.45 | 784.7K |
| Oct 14, 2026 | $1.50 | $1.52 | $1.43 | $1.47 | 1.08M |
| Oct 13, 2026 | $1.62 | $1.62 | $1.48 | $1.48 | 1.19M |
| Oct 12, 2026 | $1.62 | $1.70 | $1.56 | $1.62 | 1.6M |
| Oct 9, 2026 | $1.57 | $1.63 | $1.56 | $1.63 | 676.09K |
| Oct 8, 2026 | $1.62 | $1.62 | $1.54 | $1.57 | 1.16M |
| Oct 7, 2026 | $1.63 | $1.64 | $1.595 | $1.63 | 406.02K |
| Oct 6, 2026 | $1.68 | $1.68 | $1.62 | $1.65 | 504.65K |
| Oct 5, 2026 | $1.63 | $1.71 | $1.60 | $1.67 | 720.69K |
| Oct 2, 2026 | $1.65 | $1.665 | $1.62 | $1.635 | 622.64K |
| Oct 1, 2026 | $1.66 | $1.6861 | $1.55 | $1.63 | 1.97M |
| Sep 30, 2026 | $1.67 | $1.69 | $1.64 | $1.66 | 678.47K |
| Sep 29, 2026 | $1.66 | $1.70 | $1.63 | $1.65 | 382.27K |
| Sep 28, 2026 | $1.69 | $1.69 | $1.62 | $1.65 | 471.63K |
The latest Smart Investors Daily articles mentioning PRQR.
Company
Market Activity
Research & News
PRQR research
Company profile and research snapshot.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 1, 2026 | Chardan Capital | Buy | — |
| Aug 20, 2026 | B of A Securities | Buy | — |
| Jun 29, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Jones Trading | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on
Benzinga · Oct 1, 2026
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
SeekingAlpha · Sep 30, 2026
2026-09-30. The following slide deck was published by ProQR Therapeutics N.V.
SeekingAlpha · Sep 30, 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call September 30, 2026 11:00 AM EDTCompany ParticipantsSarah Kiely - Vice President of Investor...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRQR.
